FDA advisory panel split over Sanofi-Lexicon diabetes drug

Independent experts on an FDA advisory panel were equally split when voting on whether to approve an oral treatment for type 1 diabetes developed by Lexicon Pharmaceuticals Inc and France's Sanofi SA.